Novo Nordisk and Hims & Hers Reach Distribution Agreement for Wegovy and Ozempic, Ending Patent Litigation
Novo Nordisk and the health site Hims & Hers just signed a major deal. This new partnership lets people…
-
-
Wegovy Portfolio Update: Focus Shifts to Oral Pill as Injectable Sales Peak
Novo Nordisk has introduced a new oral version of its popular weight-loss drug, Wegovy. Many patients are used to…
-
Novo Nordisk Slashes Wegovy and Ozempic Prices by Up to 50% in Major U.S. Market Shake-Up
Novo Nordisk will slash U.S. list prices for its blockbuster drugs Wegovy and Ozempic by up to 50%. The…
-
CVS Caremark Review: Coverage and Access for Wegovy
CVS Caremark plays a central role in shaping prescription drug access for millions of Americans. As one of the…
-
Novo Nordisk Redefines Obesity Care Access and Market Value Through New Oral Wegovy
Wegovy’s oral formulation for chronic weight management was recently authorized by the Food and Drug Administration. This drug helps…
-
Oral Wegovy Formulation Now Available for Weight Management Following FDA Approval
Novo Nordisk just released the first oral glucagon-like peptide-1 receptor agonist for managing weight. Early in January 2026, pharmacies…
-
Obesity and GLP-1 Pills: Clinical Differences Explained
The landscape of metabolic health is undergoing its most significant transformation since the discovery of insulin. For the past…
-
Oral GLP-1 Orforglipron Helps Patients Maintain Weight Loss After Stopping Injectable GLP-1 Drugs
A new phase 3 trial suggests that the investigational oral GLP-1 drug orforglipron may help people maintain weight loss…
